Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59,271.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,312 shares of the biopharmaceutical company's stock after acquiring an additional 8,298 shares during the period. New Age Alpha Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $5,921,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $802,036,000. Amundi grew its position in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P increased its stake in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock worth $156,284,000 after buying an additional 219,162 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $127,489,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Finally, Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Trading Up 1.0 %

Shares of REGN traded up $5.97 during mid-day trading on Wednesday, reaching $622.97. The stock had a trading volume of 439,878 shares, compared to its average volume of 936,410. Regeneron Pharmaceuticals, Inc. has a 52-week low of $610.10 and a 52-week high of $1,211.20. The firm has a market cap of $68.11 billion, a price-to-earnings ratio of 16.27, a P/E/G ratio of 2.34 and a beta of 0.27. The business's fifty day moving average is $681.52 and its 200 day moving average is $788.06. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the business posted $11.86 EPS. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.